浩欧博(688656.SH)：2025年度净利润2341.81万元，同比下降36.37%

Core Viewpoint - The company, Haooubo (688656.SH), reported a decline in key financial metrics for the fiscal year 2025, indicating challenges in sales and profitability due to macroeconomic factors and increased operational costs [1] Financial Performance - The company achieved an operating revenue of 398.40 million yuan, a decrease of 0.98% compared to the same period last year [1] - The operating profit was 26.66 million yuan, down 35.57% year-on-year [1] - The net profit attributable to the parent company's shareholders was 23.42 million yuan, reflecting a decline of 36.37% from the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 14.94 million yuan, which is a significant drop of 58.36% year-on-year [1] Operational Challenges - The overall sales scale experienced a slight decline due to the impact of the macro market environment and related policy adjustments, affecting financial indicators such as operating revenue and net profit [1] - The expansion of the company's automated instrument deployment led to increased depreciation expenses, contributing to a rise in total operational costs [1] - The new building for fundraising projects has been put into use, resulting in a year-on-year increase in depreciation within fixed costs [1] - The company increased its marketing investment for the desensitization drug Otuok, alongside rising clinical registration costs related to the drug [1]